The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3b, randomized, parallel-group, multicenter, active-controlled, open-label
study of the efficacy and safety of infliximab compared with methotrexate (MTX) in the
treatment of moderate to severe psoriasis in adults who were diagnosed with moderate to
severe plaque-type psoriasis for at least 6 months prior to screening (subjects with
concurrent psoriatic arthritis may also be enrolled).